Skip to main content
ViGenCell Inc. logo

ViGenCell Inc. — Investor Relations & Filings

Ticker · 308080 ISIN · KR7308080001 KO Professional, scientific and technical activities
Open in API
Filings indexed 134 across all filing types
Latest filing 2023-03-07 Proxy Solicitation & In…
Country KR South Korea
Listing KO 308080

About ViGenCell Inc.

https://www.vigencell.com/en/

ViGenCell Inc. is a biotechnology company specializing in the development of immune cell therapies. The company focuses on creating treatments for cancer and other incurable diseases by enhancing a patient's own immunity. Its core technologies include the ViTier platform, which utilizes antigen-specific killer T cells to target and remove cancer cells, and the ViRanger platform, a T-cell gene therapy technology. These proprietary platforms form the basis of its pipeline of novel immune cell therapeutics designed to prolong life and improve patient outcomes.

Recent filings

Filing Released Lang Actions
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Vigencell Co., Ltd. It details the meeting date, location, agenda items (financial statement approval, board appointments, etc.), and information regarding proxy voting and management references. This document is a standard proxy statement/notice for an upcoming shareholder meeting, which falls under the 'Proxy Solicitation & Information Statement' category.
2023-03-07 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a shareholder meeting (주주총회소집결의) issued by ViGenCell. It outlines the date, location, agenda items (such as financial statement approval and director appointments), and details regarding board resolutions. This type of document is a standard proxy solicitation or notice of meeting material sent to shareholders to inform them of upcoming voting items.
2023-02-22 Korean
투자판단관련주요경영사항(재발성 교모세포종 치료제 VT-Tri(2)의 식품의약품안전처 제1상 임상시험계획(IND) 자진취하)
Legal Proceedings Report Classification · 100% confidence The document is a regulatory disclosure filed by ViroMed (바이젠셀) regarding the voluntary withdrawal of a Phase 1 clinical trial application (IND) for a glioblastoma treatment. This is a specific corporate event disclosure regarding clinical trial status, which falls under the category of general regulatory announcements for material business events that do not fit into specific financial reporting categories like 10-K or IR.
2023-02-08 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from a Korean company (Vigencell) announcing a significant change (over 30%) in its financial structure (revenue/profit/loss) compared to the previous fiscal year. This is a standard 'Earnings Release' or 'Preliminary Financial Results' announcement required by the Korea Exchange (KRX) for listed companies to disclose material financial changes before the final audited report is published. It contains key financial highlights, reasons for the change, and a disclaimer that it is based on internal data prior to external audit. FY 2022
2023-02-08 Korean
주주명부폐쇄기간또는기준일설정
Regulatory Filings Classification · 95% confidence The document is a short regulatory announcement regarding the setting of a record date for a shareholder meeting (Annual General Meeting). It is under 5,000 characters and serves as a formal notification of a corporate event rather than a full report or proxy statement. Given it is a standard regulatory disclosure regarding shareholder rights and meeting preparation, it fits best under the general regulatory filing category.
2022-12-15 Korean
분기보고서 (2022.09)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'ViGenCell' (바이젠셀) for the 3rd quarter of 2022. It contains detailed financial statements, business descriptions, management analysis, and governance information, which aligns with the definition of an Interim/Quarterly Report (IR). 9M 2022
2022-11-14 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.